A review of the pharmacological interactions of ivermectin in several animal species

Current Drug Metabolism

Volumn 10, Issue 4, 2009, Pages 359-368

  González Canga, Aránzazu ^a   Fernández Martínez, Nélida ^a   Sahagún Prieto, Ana ^a   Diez Liébana, M José ^a   Sierra Vega, Matilde ^a   García Vieitez, Juan J ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

Ivermectin; Pharmacodynamic interactions; Pharmacokinetic interactions; Veterinary

Indexed keywords

ABAMECTIN; ALBENDAZOLE; ANTINEMATODAL AGENT; CETIRIZINE; CLORSULON; CLOSANTEL; CYCLOSPORIN A; CYTOCHROME P450; DIETHYLCARBAMAZINE; DORAMECTIN; DOXYCYCLINE; ERYTHROMYCIN; FENBENDAZOLE; FEXOFENADINE; GLYCOPROTEIN P; HEXOBARBITAL; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; LEVAMISOLE; LOPERAMIDE; MACROLIDE; MOXIDECTIN; PHENAZONE; PYRANTEL EMBONATE; RAFOXANIDE; TRICLABENDAZOLE; TRIFLUOPERAZINE; UNINDEXED DRUG; VERAPAMIL;

ANIMAL PARASITOSIS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; PASTURE; REVIEW; RUMINANT STOMACH; SHEEP; VETERINARY MEDICINE;

ANIMALS; ANTIPARASITIC AGENTS; DRUG INTERACTIONS; IVERMECTIN; MODELS, BIOLOGICAL; PARASITIC DISEASES, ANIMAL; SPECIES SPECIFICITY;

EID: 68349128291     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009788498969     Document Type: Review

References (89)

1. Shoop, W.L.; Mrozik, H.; Fisher, M.H. Structure and activity of avermectins and milbemycins in animal health. Vet. Parasitol., 1995, 59 (2), 139-156.
2. Omura, S. Ivermectin: 25 years and still going strong. Int. J. Antimicrob. Agents., 2008, 31 (2), 91-98.
3. Kaplan, R.M. Drug resistance in nematodes of veterinary importance: a status report. Trends Parasitol., 2004, 20 (10), 477-481.
4. Wolstenholme, A.J.; Fairweather, I.; Prichard, R.; von Samson-Himmelstjerna, G.; Sangster, N.C. Drug resistance in veterinary helminths. Trends Parasitol., 2004, 20 (10), 469-476.
5. Jabbar, A.; Iqbal, Z.; Kerboeuf, D.; Muhammad, G.; Khan, M.N.; Afaq, M. Anthelmintic resistance: the state of play revisited. Life Sci., 2006, 79 (26), 2413-2431.
6. Behnke, J.M.; Buttle, D.J.; Stepek, G.; Lowe, A.; Duce, I.R. Developing novel anthelmintics from plant cysteine proteinases. Parasit. Vectors, 2008, 1 (1), 29.
7. González Canga, A.; Sahagún Prieto, A.M.; Diez Liébana, M.J.; Fernández Martínez, N.; Sierra Vega, M.; García Vieitez, J.J. The pharmacokinetics and interactions of ivermectin in humans: a mini-review. A.A.P.S. J., 2008, 10 (1), 42-46.
8. González Canga, A.; Sahagún Prieto, A.M.; Diez Liébana, M.J.; Fernández Martínez, N.; Sierra Vega, M.; García Vieitez, J.J. The pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet. J., 2009, 179 (1), 25-37.
9. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 1993, 62, 385-427.
10. Sharom, F.J. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol., 1997, 160 (33), 161-175.
11. Ho, R.H.; Kim, R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther., 2005, 78 (3), 260-277.
12. Alvinerie, M.; Dupuy, J.; Eeckhoutte, C.; Sutra, J.F. Enhanced absorption of pour-on ivermectin formulation in rats by co-administration of the multidrug-resistant-reversing-agent verapamil. Parasitol. Res., 1999, 85 (11), 920-922.
13. Schinkel, A.H. The physiological function of drug-transporting P-glycoproteins. Cancer Biol., 1997, 8 (3), 161-167.
14. Molento, M.B.; Lifschitz, A.; Sallovitz, J.; Lanusse, C. Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitol. Res., 2004, 92 (2), 121-127.
15. Laffont, C.M.; Toutain, P.L.; Alvinerie, M.; Bousquet-Mélou, A. Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab. Dispos., 2002, 30 (6), 626-630.
16. Molento, M.B.; Prichard, R.K. Effects of the multidrug-resistance-reversing agents verapamil and CL 347,099 on the efficacy of ivermectin or moxidectin against unselected and drug-selected strains of Haemonchus contortus in jirds (Meriones unguiculatus). Parasitol. Res., 1999, 85 (12), 1007-1011.
17. Borges, F.; Silva, H.; Buzzolini, C.; Soares, V.; Costa, A.; Molento, M. In Use of Verapamil to Increase Anthelmintic Efficacy of Ivermectin Against Drug-Selected Strain of Haemonchus contortus. Proceedings of the 20th International Conference of the World Association for the Advancement of Veterinary Parasitology, VetLearn Foundation, Christchurch (New Zealand), 2005, p. 73.
18. Lifschitz, A.; Virkel, G.; Sallovitz, J.; Pis, A.; Imperiale, A.; Lanusse, C.E. Loperamide modifies the tissue disposition kinetics of ivermectin in rats. J. Pharm. Pharmacol., 2003, 56 (1), 61-67.
19. Ballent, M.; Lifschitz, A.; Virkel, G.; Sallovitz, J.; Lanusse, C. Involvement of P-glycoprotein on ivermectin kinetic behaviour in sheep: itraconazole-mediated changes on gastrointestinal disposition. J. Vet. Pharmacol. Ther., 2007, 30 (3), 242-248.
20. Marriner, S.E.; McKinnon, I.; Bogan, J.A. The pharmacokinetics of ivermectin after oral and subcutaneous administration to sheep and horses. J. Vet. Pharmacol. Ther., 1987, 10 (2), 175-179.
21. Imperiale, F.; Lifschitz, A.; Sallovitz, J.; Virkel, G.; Lanusse, C. Comparative depletion of ivermectin and moxidectin milk residues in dairy sheep after oral and subcutaneous administration. J. Dairy Res., 2004, 71 (4), 427-323.
22. Lifschitz, A.; Virkel, G.; Ballent, M.; Sallovitz, J.; Pis, A.; Lanusse, C. Moxidectin and ivermectin metabolic stability in sheep ruminal and abomasal contents. J. Vet. Pharmacol. Ther., 2005, 28 (5), 411-418.
23. Ballent, M.; Lifschitz, A.; Virkel, G.; Sallovitz, J.; Lanusse, C. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metab. Dispos., 2006, 34 (3), 457-463.
24. Lifschitz, A.; Ballent, M.; Virkel, G.; Sallovitz, J.; Lanusse, C. Sex-related differences in the gastrointestinal disposition of ivermectin in the rat: P-glycoprotein involvement and itraconazole modulation. J. Pharm. Pharmacol., 2006, 58 (8), 1055-1062.
25. Hugnet, C.; Lespine, A.; Alvinerie, M. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. J. Pharm. Pharmacol. Sci., 2007, 10 (3), 311-318.
26. Mayer, U.K.; Glos, K.; Schmid, M.; Power, H.T.; Bettenay, S.V.; Mueller, R.S. Adverse effects of ketoconazole in dogs: a retrospective study. Vet. Dermatol., 2008, 19 (4), 199-208.
27. Alvinerie, M.; Dupuy, J.; Kiki-Mvouaka, S.; Sutra, J.F.; Lespine, A. Ketoconazole increases the plasma levels of ivermectin in sheep. Vet. Parasitol., 2008, 157 (1-2), 117-122.
28. Kwei, G.Y.; Alvaro, R.F.; Chen, Q.; Jenkins, H.J.; Hop, C.E.; Keohane, C.A., Ly, V.T.; Strauss, J.R.; Wang, R.W.; Wang, Z.; Pippert, T.R.; Umbenhauer, D.R. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos., 1999, 27 (5), 581-587.
29. Roulet, A.; Puel, O.; Gesta, S.; Lepage, J.F.; Drag, M.; Soll, M.; Alvinerie, M.; Pineau, T. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol., 2003, 460 (2-3), 85-91.
30. Schinkel, A.H.; Smit, J.J.M.; Van Telligen, O.; Beijnen, J.H.; Wagenaar, E.; Van Deemter, L.; Mol, C.A.; van der Valk, M.A.; Robanus-Maandag, E.C.; te Riele, H.P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensivity to drugs. Cell, 1994, 77 (4), 491-502.
31. Marques-Santos, L.F.; Bernardo, R.R.; Paula, E.; Rumjanek, V.M. Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice. Pharmacol. Toxicol., 1999, 84 (3), 125-129.
32. Nobmann, S.; Bauer, B.; Fricker, G. Ivermectin excretion by isolated functionally intact brain endothelial capillaries. Br. J. Parasitol., 2001, 132 (3), 722-728.
33. El Nahas, A.F.; El Ashmawy, I.M. Effect of ivermectin on male fertility and its interaction with P-glycoprotein inhibitor (verapamil) in rats. Environ. Toxicol. Pharmacol., 2008, 26 (2), 206-211.
34. Olsén, L.; Ingvast-Larsson, C.; Larsson, P.; Broström, H.; Bondesson, U.; Sundqvist, M.; Tjälve, H. Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. J. Vet. Pharmacol. Ther., 2006, 29 (2), 129-135.
35. Olsén, L.; Ingvast-Larsson, C.; Bondesson, U.; Broström, H.; Tjälve, H.; Larsson, P. Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. J. Vet. Pharmacol. Ther., 2007, 30 (3), 194-200.
36. Barber, S.; Bowles, V.; Lespine, A.; Alvinerie, M. The comparative serum disposition kinetics of subcutaneous administration of doramectin, ivermectin and moxidectin in the Australian merino sheep. J. Vet. Pharmacol. Ther., 2003, 26 (5), 343-348.
37. Dupuy, J.; Larrieu, G.; Sutra, J.F.; Lespine, A.; Alvinerie, M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet. Parasitol, 2003, 112 (4), 337-347.
38. Zeng, Z.; Andrew, N.W.; Woda, J.M.; Halley, B.A.; Crouch, L.S.; Wang, R.W. Role of cytochrome P450 isoforms in the metabolism of abamectin and ivermectin in rats. J. Agric. Food Chem., 1996, 44 (10), 3374-3378.
39. Zeng, Z.; Andrew, N.W.; Arison, B.H.; Luffer-Atlas, D.; Wang, R.W. Identification of cytochrome P450 3A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica, 1998, 28 (3), 313-321.
40. 14C moxidectin by hepatic microsomes from various species. Vet. Res. Commun., 2001, 25 (5), 345-354.
41. Ito, K.; Kusuhura, H.; Sugiyama, Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption: theoretical approach. Pharm. Res., 1999, 16 (2), 225-231.
42. Lin, J. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Exp. Opin. Drug Metab. Toxicol., 2007, 3 (1), 81-92.
43. Merino, G.; Molina, A.J.; García, J.L.; Pulido, M.M.; Prieto, J.G.; Álvarez, A.I. Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. Int. J. Pharm., 2003, 263 (1-2), 123-132.
44. Edwards, G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J., 2003, 2 (1), S8.
45. Álvarez, L.; Lifschitz, A.; Entrocasso, C.; Manazza, J.; Mottier, L.; Borda, B.; Virkel, G.; Lanusse, C. Evaluation of the interaction between ivermectin and albendazole following their combined use in lambs. J. Vet. Pharmacol. Ther., 2008, 31 (3), 230-239.
46. Lifschitz, A.; Virkel, G.; Ballent, M.; Sallovitz, J.; Lanusse, C. Combined use of ivermectin and triclabendazole in sheep: in vitro and inc vivo characterisation of their pharmacological interaction. Vet. J., 2008, in press.
47. Chiu, S.H.L.; Sestokas, E.; Taub, R.; Buhs, R.P. Metabolic disposition of ivermectin in tissues of cattle, sheep, and rats. Drug Metab. Dispos., 1986, 14 (5), 590-600.
48. Chiu, S.H.L.; Sestokas, E.; Taub, R.; Green, M.; Baylis, F.P.; Jacob, T.A.; Lu, A.Y.H. Metabolic disposition of ivermectin in swine. J. Agric. Biol. Chem., 1990, 38 (11), 2079-2085.
49. Alvinerie, M.; Tardieu, D.; Sutra, J.F.; Bojensen, G.; Galtier, P. In Metabolic profile of ivermectin in goats: an in vivo and in vitro evaluation. Proceedings of the 6th International Congress, European Association for Veterinary Pharmacology and Toxicology. Lees, P., Ed.; Blackwell Scientific Publications, Edinburgh, 1994, 262.
50. Skálová, L.; Szotáková, B.; Machala, M.; Neča, J.; Lamka, J.; Ducháček, L.; Kvasnickova, E. Effect of ivermectin on induction of cytochromes P450 in male rats. Chem. Papers, 2000, 54 (4), 249-253.
51. Skálová, L.; Szotáková, B.; Machala, M.; Neča, J.; Souček, P.; Havlasová, J.; Wsol, V.; Kridova, L.; Kvasnickova, E.; Lamka, J. Effect of ivermectin on activities of cytochrome P450 isoenzymes in mouflon (Ovis musimon) and fallow deer (Dama dama). Chem. Biol. Interact., 2001, 137 (2), 155-167.
52. Sibille, P.; Calleja, C.; Carreras, F.; Bigot, K.; Galtier, P.; Boulard, C. Fasciola hepatica: influence of gender and liver biotransformations on flukicide treatment efficacy of rats infested and cured with either clorsulon-ivermectin or triclabendazole. Exp. Parasitol., 2000, 94 (4), 227-237.
53. Bohlen, D.M.; Burrows, G.E.; Clarke, C.R.; Burrows, S.L. Lack of effect of ivermectin on antipyrine and erythromycin disposition in calves. J. Vet. Pharmacol. Therap., 1995, 18 (6), 476-478.
54. Inaam, E.A.D.; El Tayeb, I.B.; Sania, A.S.; Hassan, T. The effect of Haemonchus contortus infection and treatment with ivermectin on drug-metabolizing enzymes. J. Anim. Vet. Adv., 2007, 6 (1), 123-128.
55. El Banna, H.; Goudah, A.; El Zorba, H.; Abd El Rahman, S. Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. Parasitol. Res., 2008, 102 (6), 1337-1342.
56. Fuhr, U. What is the true risk of a pharmacokinetic drug-drug interaction? Eur. J. Clin. Pharmacol., 2007, 63 (10), 897-899.
57. Clark, J.N.; Daurio, C.P.; Plue, R.E.; Wallace, D.H.; Longhofer, S.L. Efficacy of ivermectin and pyrantel pamoate combined in a chewable formulation against heartworm, hookworm, and ascarid infections in dogs. Am. J. Vet. Res., 1992a, 53 (4), 517-520.
58. Clark, J.N.; Pulliam, J.D.; Daurio, C.P. Safety study of a beef-based chewable tablet formulation of ivermectin and pyrantel pamoate in growing dogs, pups, and breeding adult dogs. Am. J. Vet. Res., 1992c, 53 (4), 608-612.
59. Nolan, T.J.; Hawdon, J.M.; Longhofer, S.L.; Daurio, C.P.; Schad, G.A. Efficacy of an ivermectin/pyrantel pamoate chewable formulation against the canine hookworms, Uncinaria stenocephala and Ancylostoma caninum. Vet. Parasitol., 1992, 41 (1-2), 121-125.
60. Labartiie, N.V.; Nobre E Castro, M.C.; Cruz, J.B.; Ramadinhaj, R.H.; Soares, A.M. Efficacy of ivermectin plus pyrantel in a chewable formulation for heartworm prevention and treatment of hookworm and ascarid infections. Rev. Bras. Parasitol. Vet., 1996, 5 (1), 1-6.
61. 3H]ivermectin in the dog following oral administration of a beef-based chewable formulation containing ivermectin alone or in combination with pyrantel pamoate. J. Vet. Pharmacol. Ther., 1992b, 15 (2), 217-220.
62. Hoerauf, A.; Mand, S.; Adjei, O.; Fleischer, B.; Büttner, D. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet, 2001, 537 (9266), 1415-1416.
63. Bazzocchi, C.; Mortarino, M.; Grandi, G.; Kramer, L.H.; Genchi, C.; Bandi, C.; Genchi, M.; Sacchi, L.; McCall, J.W. Combined ivermectin and doxycycline treatment has microfilaricidal and adulticidal activity against Dirofilaria immitis in experimentally infected dogs. Int. J. Parasitol., 2008, 38 (12), 1401-1410.
64. McCall, J.W.; Genchi, C.; Kramer, L.; Guerrero, J.; Dzimianski, M.T.; Supakorndej, P.; Mansour, A.M.; McCall, S.D.; Supakorndej, N.; Grandi, G.; Carson, B. Heartworm and Wolbachia: therapeutic implications. Vet. Parasitol., 2008, 158 (3), 204-214.
65. Chansiri, G.; Khawsak, P.; Phantana, S.; Sarataphan, N.; Chansiri, K. The efficacy of a single-oral-dose administration of ivermectin and diethylcarbamazine on the treatment of feline Brugia malayi. Southeast Asian J. Trop. Med. Public Health, 2005, 36 (5), 1105-1109.
66. Meiser, H.; Hagedorn, H.W.; Majzoub, M.; Schulz, R. Detection of levamisole and ivermectin in organ samples from a perished collie. Berl. Münch. Tierärztl. Wschrschr., 2001, 114 (5-6), 210-215.
67. Reinhardt, C.D.; Hutcheson, J.P.; Nichols, W.T. A fenbendazole oral drench in addition to an ivermectin pour-on reduces parasite burden and improves feedlot and carcass performance of finishing heifers compared with endectocides alone. J. Anim. Sci., 2006, 84 (8), 2243-2250.
68. Entrocasso, C.; Álvarez, L.; Manazza, J.; Lifschitz, A.; Borda, B.; Virkel, G.; Mottier, L.; Lanusse, C. Clinical efficacy assessment of the albendazole-ivermectin combination in lambs parasitized with resistant nematodes. Vet. Parasitol., 2008, 155 (3-4), 249-256.
69. Borges, F.A.; Silva, H.C.; Buzzulinia, C.; Soares, V.E.; Santos E.; Oliveira, G.P.; Costa, A.J. Endectocide activity of a new longaction formulation containing 2.25% ivermectin + 1.25% abamectin in cattle. Vet. Parasitol., 2008, 155 (3-4), 299-307.
70. Conder, G.A.; Thompson, D.P.; Johnson, S.S. Demonstration of co-resistance of Haemonchus contortus to ivermectin and moxidectin. Vet. Rec., 1993, 132 (26), 651-652.
71. Watson, T.G.; Hosking, B.C.; Leathwick, D.M.; McKee, P.F. Ivermectin-moxidectin side resistance by Ostertagia species isolated from goats and passaged to sheep. Vet. Rec., 1996, 138 (19), 472-473.
72. Borgsteede, F.H.M.; Taylor, S.M.; Gaasenbeek, C.P.H.; Couper, A.; Cromie, L. The efficacy of an ivermectin/closantel injection against experimentally induced infections and field infections with gastrointestinal nematodes and liver fluke in cattle. Vet. Parasitol., 2008, 155 (3-4), 235-241.
73. Courtney, C.H.; Shearer, J.K.; Plue, R.E. Efficacy and safety of clorsulon used concurrently with ivermectin for control of Fasciola hepatica in Florida beef cattle. Am. Vet. Med. Assoc., 1985, 46 (6), 1245-1246.
74. Sangster, N.C.; Bannan, S.C.; Weiss, A.S.; Nulf, S.C.; Klein, R.D.; Geary, T.G.. Haemonchus contortus: sequence heterogeneity of internucleotide binding domains from P-glycoprotein and an association with avermectine/milbemycin resistance. Exp. Parasitol., 1999, 91 (3), 250-257.
75. Xu, M.; Molento, M.; Blackhall, W.; Ribeiro, P.; Beech, R.; Prichard, R.K. Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Mol. Biochem. Parasitol., 1998, 91 (2), 327-335.
76. Mottier, L.; Álvarez, L.; Fairweather, I.; Lanusse, C. Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect. J. Parasitol., 2006, 92 (6), 1355-1360.
77. Casado, N.; Moreno, M.J.; Urrea-París, M.A.; Rodríguez-Caabeiro, F. Could ivermectin have a synergic effect with albendazole in hydatidosis therapy?: in vitro studies. Parasitol. Res., 2002, 88 (2), 153-159.
78. Moreno, M.J.; Casado, N.; Urrea-París, M.A.; Rodríguez-Caabeiro, F. Could ivermectin have a synergic effect with albendazole in hidatidosis therapy?: in vivo studies. Parasitol. Res., 2002, 88 (6), 563-567.
79. Rehbein, S.; Holste, J.E.; Doucet, M.Y.; Fenger, C.; Paul, A.J.; Reinemeyer, C.R.; Smith, L.L.; Yoon, S.; Marley, S.E. Field efficacy of ivermectin plus praziquantel oral paste against naturally acquired gastrointestinal nematodes and cestodes of horses in North America and Europe. Vet. Ther., 2003, 4 (3), 220-227.
80. Marley, S.E.; Hutchens, D.E.; Reinemeyer, C.R.; Holste, J.E.; Paul, A.J.; Rehbein, S. Antiparasitic activity of an ivermectin and praziquantel combination paste in horses. Vet. Ther., 2004, 5 (2), 105-119.
81. Mercier, P.; Alves-Branco, F.; Sapper, M.F.; White, C.R. Evaluation of the safety of ivermectin-praziquantel administered orally to pregnant mares. Am. J. Vet. Res., 2003, 64 (10), 1221-1224.
82. FDA (Food and Drug Administration). http://www.fda.gov/cvm/CVM_Updates/ ComfortisSafety.htm. [Internet] 2008 [(Accessed January 11, 2009].
83. Trailović, S.M.; Varagi, V.M. The effect of ivermectin on convulsions in rats produced by lidocaine and strychnine. Vet. Res. Commun., 2007, 31 (7), 863-872.
84. Souza-Spinosa, H.; Stilck, S.R.; Bernardi, M.M. Possible anxiolytic effects of ivermectin in rats. Vet. Res. Commun., 2002, 26 (4), 309-321.
85. 1a. Eur. J. Pharmacol., 1979, 56 (3), 273-276.
86. Drexler, G.; Sieghart, W. Evidence for association of a high affinity avermectin binding site with the benzodiazepine receptors. Eur. J. Pharmcol., 1984, 101 (3-4), 201-207.
87. Williams, M.; Risley, E.A. Ivermectin interactions with benzodiazepine receptors in rat cortex and cerebellum in vitro. J. Neurochem., 1984, 42 (3), 745-753.
88. Crichlow, E.C.; Mishra, P.R.; Crawford, R.D. Anticonvulsant effects of ivermectin in genetically-epileptic chickens. Neuropharmacology, 1986, 25 (10), 1085-1088.
89. Mayer, T.W.; Horton, M.L. Modulation of monomethylhydrazine-induced seizures by ivermectin. Toxicol. Lett., 1991, 57 (2), 167-173.